文献速递呼吸衰竭与机械通气重症综合管理与镇静镇痛

地塞米松与雷帕霉素协同保护促炎细胞因子诱导的肺泡上皮细胞损伤

Synergistic cytoprotection by co-treatment with dexamethasone and rapamycin against proinflammatory cytokine-induced alveolar epithelial cell injury.
PubMed 文献 · J Intensive Care · 2019-02-07
一句话结论体外研究显示地塞米松10 nM与雷帕霉素1 nM联用对炎性细胞因子诱导的A549肺泡上皮细胞损伤有协同细胞保护作用。

该研究在体外用TNF-α、IL-1β、IFN-γ混合刺激人肺泡上皮A549细胞模拟脓毒症相关急性肺损伤,筛选抗炎药物的细胞保护作用。结果显示地塞米松或雷帕霉素单药均呈剂量依赖性显著减轻细胞因子诱导的细胞毒性,两药同时给药具有协同细胞保护作用,所用剂量(地塞米松10 nM、雷帕霉素1 nM)远低于文献报道的临床血药浓度。两药联用还观察到c-Jun抑制与Akt激活的增强,作者认为可能介导该保护效应,并提出联合抗炎药物可能为脓毒症相关肺泡上皮损伤提供有前景的治疗选择。

要点

  • 地塞米松或雷帕霉素单药均以剂量依赖性方式显著减轻TNF-α、IL-1β、IFN-γ诱导的A549细胞毒性。
  • 地塞米松10 nM与雷帕霉素1 nM同时给药对细胞因子诱导的细胞毒性具有协同细胞保护作用。
  • 所用剂量(地塞米松10 nM、雷帕霉素1 nM)远低于文献报道的临床血药浓度。
  • 两药联用下c-Jun抑制与Akt激活均增强,作者认为可能解释协同细胞保护效应。
  • 作者提出地塞米松与雷帕霉素等抗炎药物联合给药是脓毒症相关肺泡上皮损伤有前景的治疗选择。

适用人群与场景

  • 体外研究:人肺泡上皮细胞来源的A549细胞,经TNF-α、IL-1β、IFN-γ混合刺激模拟脓毒症相关急性肺损伤。

处置流程与药物剂量

  • 在细胞因子刺激下,A549细胞同时给予地塞米松10 nM与雷帕霉素1 nM进行共处理。

研究设计与关键结果

  • 体外研究:地塞米松或雷帕霉素单药均以剂量依赖性方式显著减轻细胞因子诱导的A549细胞毒性。
  • 地塞米松10 nM与雷帕霉素1 nM同时给药具有协同细胞保护作用,所用剂量远低于文献报道的各自临床血药浓度。
  • 细胞因子刺激下两药共处理时,c-Jun抑制与Akt激活均出现明显增强,作者认为可能介导协同细胞保护效应。

证据类型、等级与局限

  • 证据类型:体外细胞实验(A549细胞),非临床研究。
  • 局限:原文未报告局限性。

对床旁实践的改变

  • 作者认为,地塞米松与雷帕霉素等抗炎药物的联合给药为脓毒症相关肺泡上皮损伤提供了有前景的治疗选择;该结论来自体外A549细胞实验,非临床推荐。

提炼说明

  • 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开

BACKGROUND: One of the main pathophysiological manifestations during the acute phase of sepsis is massive production of proinflammatory mediators. Clinical trials involving direct suppression of inflammatory mediators to relieve organ dysfunction in sepsis have been extensively performed; however, the clinical outcomes of such trials remain far from satisfactory. Given the need for better sepsis treatments, we have screened various agents with anti-inflammatory properties for cytoprotective effects. In this study, we identified dexamethasone and rapamycin as clinically applicable candidates with favorable synergistic effects against inflammatory cytokine-induced cytotoxicity in vitro and further explored the molecular mechanisms underlying the augmented cytoprotective effects exerted by co-treatment with both drugs.

METHODS: Human alveolar epithelial cell-derived A549 cells were stimulated with a mixture of inflammatory cytokines, TNF-alpha, IL-1beta, and IFN-gamma, which induce cellular injury, including apoptosis. This in vitro model was designed to simulate acute lung injury (ALI) associated with sepsis. The cells were co-treated with dexamethasone and rapamycin under cytokine stimulation. Conditioned medium and cell lysates were subjected to further analysis.

RESULTS: Either dexamethasone or rapamycin significantly attenuated cytokine-induced cytotoxicity in A549 cells in a dose-dependent manner. In addition, the simultaneous administration of dexamethasone and rapamycin had a synergistic cytoprotective effect. The applied doses of dexamethasone (10 nM) and rapamycin (1 nM) were considerably below the reported plasma concentrations of each drug in clinical setting. Interestingly, distinct augmentation of both of c-Jun inhibition and Akt activation were observed when the cells were co-treated with both drugs under cytokine stimulation.

CONCLUSIONS: A synergistic protective effect of dexamethasone and rapamycin was observed against cytokine-induced cytotoxicity in A549 cells. Augmentation of both of c-Jun inhibition and Akt activation were likely responsible for the cytoprotective effect. The combined administration of anti-inflammatory drugs such as dexamethasone and rapamycin offers a promising treatment option for alveolar epithelial injury associated with sepsis.

来源:J Intensive Care,查看原文。版权归原作者所有。

参考来源

  1. Kuwajima K, Chang K, Furuta A, et al. Synergistic cytoprotection by co-treatment with dexamethasone and rapamycin against proinflammatory cytokine-induced alveolar epithelial cell injury. J Intensive Care. 2019. PMID: 30774959. doi:10.1186/s40560-019-0365-5

供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。